Notable Labs, Ltd.
US ˙ OTCPK

Introduction

This page provides a comprehensive analysis of the known insider trading history of Thomas I H Dubin. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Thomas I H Dubin has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:NTBL / Notable Labs, Ltd. Director 40,247
US:US00C4W1JQ50 / Alexion Pharmaceuticals, Inc. SVP & Chief Legal Officer 65,705
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Thomas I H Dubin. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases NTBLQ / Notable Labs, Ltd. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in NTBLQ / Notable Labs, Ltd.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NTBLQ / Notable Labs, Ltd. Insider Trades
Insider Sales NTBLQ / Notable Labs, Ltd. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in NTBLQ / Notable Labs, Ltd.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NTBLQ / Notable Labs, Ltd. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Thomas I H Dubin as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-05-10 2024-05-08 4 NTBL Notable Labs, Ltd.
Ordinary Shares
A - Award 40,247 40,247
2023-10-18 3 NTBL Notable Labs, Ltd.
Ordinary Shares
0
2012-08-27 2012-08-23 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
S - Sale X -9,200 65,705 -12.28 103.87 -955,604 6,824,778
2012-08-27 2012-08-23 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
S - Sale X -24,328 74,905 -24.52 103.09 -2,507,974 7,721,956
2012-07-31 2012-07-31 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
S - Sale -680 99,233 -0.68 104.94 -71,359 10,413,511
2012-07-31 2012-07-27 4 ALXN ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock
M - Exercise -4,000 60,000 -6.25
2012-07-31 2012-07-27 4 ALXN ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock
M - Exercise -28,124 61,876 -31.25
2012-07-31 2012-07-27 4 ALXN ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock
M - Exercise -56,250 43,750 -56.25
2012-07-31 2012-07-27 4 ALXN ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock
M - Exercise -82,671 12,751 -86.64
2012-07-31 2012-07-27 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
S - Sale -668 99,913 -0.66 106.14 -70,902 10,604,766
2012-07-31 2012-07-27 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
S - Sale -28,200 100,581 -21.90 109.28 -3,081,696 10,991,492
2012-07-31 2012-07-27 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
S - Sale -68,632 128,781 -34.77 108.56 -7,450,690 13,980,465
2012-07-31 2012-07-27 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
S - Sale -51,303 197,413 -20.63 107.57 -5,518,664 21,235,716
2012-07-31 2012-07-27 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
S - Sale -16,642 248,716 -6.27 106.35 -1,769,877 26,450,947
2012-07-31 2012-07-27 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
S - Sale -6,268 265,358 -2.31 105.76 -662,904 28,064,262
2012-07-31 2012-07-27 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
M - Exercise 4,000 271,626 1.49 78.88 315,520 21,425,859
2012-07-31 2012-07-27 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
M - Exercise 28,124 267,626 11.74 42.66 1,199,770 11,416,925
2012-07-31 2012-07-27 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
M - Exercise 56,250 239,502 30.70 22.90 1,288,125 5,484,596
2012-07-31 2012-07-27 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
M - Exercise 82,671 183,252 82.19 17.98 1,486,425 3,294,871
2012-06-19 2012-06-15 4 ALXN ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock
M - Exercise -6,578 95,422 -6.45
2012-06-19 2012-06-15 4 ALXN ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock
M - Exercise -36,000 0 -100.00
2012-06-19 2012-06-15 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
S - Sale -9,011 100,581 -8.22 94.04 -847,394 9,458,637
2012-06-19 2012-06-15 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
S - Sale -33,567 109,591 -23.45 93.96 -3,153,955 10,297,170
2012-06-19 2012-06-15 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
M - Exercise 6,578 143,159 4.82 17.98 118,272 2,573,999
2012-06-19 2012-06-15 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
M - Exercise 36,000 136,581 35.79 17.65 635,400 2,410,655
2012-05-31 2012-05-29 4 ALXN ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock
M - Exercise -39,000 36,000 -52.00
2012-05-31 2012-05-29 4 ALXN ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock
M - Exercise -44,308 0 -100.00
2012-05-31 2012-05-29 4 ALXN ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock
M - Exercise -20,092 0 -100.00
2012-05-31 2012-05-29 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
S - Sale -103,400 100,581 -50.69 92.02 -9,514,485 9,255,091
2012-05-31 2012-05-29 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
M - Exercise 39,000 203,981 23.64 17.65 688,252 3,599,755
2012-05-31 2012-05-29 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
M - Exercise 44,308 164,981 36.72 11.92 527,930 1,965,749
2012-05-31 2012-05-29 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
M - Exercise 20,092 120,673 19.98 10.29 206,696 1,241,423
2012-05-14 2012-05-14 4 ALXN ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock
M - Exercise -18,088 0 -100.00
2012-05-14 2012-05-14 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
M - Exercise 18,088 100,581 21.93 8.18 147,960 822,753
2012-05-14 2012-05-10 4 ALXN ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock
M - Exercise -5,000 0 -100.00
2012-05-14 2012-05-10 4 ALXN ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock
M - Exercise -5,692 0 -100.00
2012-05-14 2012-05-10 4 ALXN ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock
M - Exercise -9,908 0 -100.00
2012-05-14 2012-05-10 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
M - Exercise 5,000 82,493 6.45 17.65 88,250 1,456,001
2012-05-14 2012-05-10 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
M - Exercise 5,692 77,493 7.93 11.92 67,849 923,717
2012-05-14 2012-05-10 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
M - Exercise 9,908 71,931 15.97 10.29 101,953 740,170
2012-03-16 2012-03-14 4 ALXN ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock
M - Exercise -20,000 20,092 -49.89
2012-03-16 2012-03-14 4 ALXN ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock
M - Exercise -21,912 0 -100.00
2012-03-16 2012-03-14 4 ALXN ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock
M - Exercise -24,000 0 -100.00
2012-03-16 2012-03-14 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
S - Sale -11,200 62,023 -15.30 89.24 -999,488 5,534,933
2012-03-16 2012-03-14 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
S - Sale -54,712 73,233 -42.76 88.72 -4,854,049 6,497,232
2012-03-16 2012-03-14 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
M - Exercise 20,000 127,935 18.53 10.29 205,800 1,316,451
2012-03-16 2012-03-14 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
M - Exercise 21,912 107,935 25.47 8.18 179,240 882,908
2012-03-16 2012-03-14 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
M - Exercise 24,000 86,023 38.70 6.90 165,600 593,559
2012-02-23 2012-02-22 4 ALXN ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock
M - Exercise -32,000 0 -100.00
2012-02-23 2012-02-22 4 ALXN ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock
M - Exercise -40,000 0 -100.00
2012-02-23 2012-02-22 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
S - Sale -5,000 62,023 -7.46 83.84 -419,200 5,200,008
2012-02-23 2012-02-22 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
S - Sale -84,871 67,023 -55.88 83.45 -7,082,485 5,593,069
2012-02-23 2012-02-22 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.001 per share
M - Exercise 32,000 151,894 26.69 5.18 165,760 786,811
2012-02-23 2012-02-22 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
M - Exercise 40,000 119,894 50.07 5.10 204,000 611,459
2012-02-06 2012-02-03 4 ALXN ALEXION PHARMACEUTICALS INC
Option to Purchase Common Stock
M - Exercise 64,000 64,000
2012-02-06 2012-02-03 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
M - Exercise 8,000 79,894 11.13
2012-01-30 2012-01-30 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
S - Sale -2,002 71,894 -2.71 74.51 -149,169 5,356,822
2012-01-30 2012-01-27 4 ALXN ALEXION PHARMACEUTICALS INC
Common Stock, par value $.0001 per share
S - Sale -663 73,896 -0.89 74.41 -49,334 5,498,601
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)